Literature DB >> 28710830

Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.

Umberto Gianelli1, Stefano Fiori1, Daniele Cattaneo2,3, Anna Bossi4, Ivan Cortinovis4, Arturo Bonometti1, Giulia Ercoli1, Cristina Bucelli2,3, Nicola Orofino2,3, Gaetano Bulfamante5, Alessandra Iurlo2,3.   

Abstract

AIMS: To evaluate whether a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in bone marrow trephine biopsies (BMBs) of primary myelofibrosis (PMF) patients may have prognostic implications. METHODS AND
RESULTS: Reticulin fibrosis, collagen deposition and osteosclerosis were graded from 0 to 3 in a series of 122 baseline BMBs. Then, we assigned to each case a comprehensive score [reticulin, collagen, osteosclerosis (RCO) score, ranging from 0 to 9] that allowed us to distinguish two groups of patients, with low-grade (RCO score 0-4) and high-grade (RCO score 5-9) stromal changes. Of 122 patients, 88 displayed a low-grade and 34 a high-grade RCO score. The latter was associated more frequently with anaemia, thrombocytopenia, peripheral blood blasts and increased lactate dehydrogenase levels. The RCO score was correlated strictly with overall mortality (P = 0.013) and International Prognostic Scoring System (IPSS) risk categories, and was able to discriminate the overall survival of both low- and high-grade patients (log-rank test: P < 0.001). Moreover, it proved to be more accurate than the European Consensus on Grading of Bone Marrow Fibrosis (ECGMF grade) in identifying high-risk patients with poor prognosis. Finally, a combined analysis of RCO scores and IPSS risk categories in an integrated clinical-pathological evaluation was able to increase the positive predictive value (PPV) for mortality in high-risk patients.
CONCLUSION: The comprehensive RCO score, obtained by histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis was prognostically significant and more accurate than ECGMF grade in identifying high-risk patients and improved PPV when applied in addition to IPSS.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  bone marrow morphology; collagen deposition; osteosclerosis; primary myelofibrosis; reticulin fibrosis

Mesh:

Substances:

Year:  2017        PMID: 28710830     DOI: 10.1111/his.13309

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

Review 1.  Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver.

Authors:  Alessandro Malara; Vittorio Abbonante; Maria Zingariello; Annarita Migliaccio; Alessandra Balduini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

2.  Evaluation of mandibular calcification on 3D volume images.

Authors:  Barbara Schreiner-Tiefenbacher; Vivian Forster; Klaudio Pauli; Walter Sutter; Marius Meier; Henning Roland; Patrick Bandura; Dritan Turhani
Journal:  Heliyon       Date:  2019-05-20

3.  The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.

Authors:  Stefanie Slot; Niels W C J van de Donk; René H J Otten; Bouke J H Boden; Josée Zijlstra; Pieter G H M Raijmakers; Sonja Zweegman
Journal:  Cancer Imaging       Date:  2021-04-20       Impact factor: 3.909

4.  Targeted sequencing of candidate gene regions for myelofibrosis in dogs.

Authors:  Amelia G Campbell; Davis M Seelig; Joan D Beckman; Katie M Minor; Daniel A Heinrich; Steven G Friedenberg; Jaime F Modiano; Eva Furrow
Journal:  J Vet Intern Med       Date:  2022-07-11       Impact factor: 3.175

5.  Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.